Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Wegovy weight-loss drug supply to be temporarily curtailed by Novo Nordisk as it ramps up production
09:19am, Thursday, 04'th May 2023
Novo Nordisk on Thursday said demand was so strong for its weight-loss injectable medicine that it will have to reduce the supply temporarily.
Novo Nordisk Stock Skids As Obesity Drug Wegovy Misses Expectations
09:16am, Thursday, 04'th May 2023
Novo Nordisk stock skidded Thursday after the company beat overall sales and profit expectations, but obesity treatment Wegovy came in light. The post Novo Nordisk Stock Skids As Obesity Drug Wegovy M
Novo Nordisk cuts some supply of Wegovy obesity drug as demand grows
07:15am, Thursday, 04'th May 2023
Karsten Munk Knudsen, chief financial officer at Novo Nordisk, says the company is halving the supply of starter doses of its Wegovy weight loss drug to ensure "continuity of care" for existing patien
Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars
06:55am, Thursday, 04'th May 2023
Novo Nordisk said Thursday that it was cutting the supply of some doses of its popular obesity drug in the U.S. as it struggles to keep up with surging demand.
Novo Nordisk: U.S. is priority for weight-loss drug over launching in new markets
05:19am, Thursday, 04'th May 2023
Novo Nordisk is prioritising U.S. supplies of its popular weight-loss drug Wegovy over launching in new markets, a senior executive told Reuters on Thursday as the Danish drugmaker struggles to keep u
2 Stocks That Could Triple Your Investment by 2030
07:20am, Wednesday, 03'rd May 2023
Novo Nordisk's stock will probably ride its semaglutide sales to the moon. SNDL's anticipated entry into the U.S. market will soon juice its growth.
V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023
04:51pm, Monday, 01'st May 2023
The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-ye
1 No-Brainer Pharma Stock to Buy With $1,000 Right Now
09:30am, Saturday, 29'th Apr 2023
Novo Nordisk is aiming to fully exploit the gold mine it developed with semaglutide. Wegovy, Rybelsus, and Ozempic are just the first few formulations to be approved.
Weight loss drug market is just beginning to take off, says Mizuho's Jared Holz
02:33pm, Friday, 28'th Apr 2023
Jared Holz, Mizuho healthcare equity strategist, joins 'The Exchange' to discuss new weight loss drugs coming to market, forecasts for market expansion in weight loss drugs, and key players in the wei
ETO: This Attractively-Valued CEF Is A Good Choice For An Income Seeker
02:46pm, Wednesday, 26'th Apr 2023
ETO: This Attractively-Valued CEF Is A Good Choice For An Income Seeker.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
10:40am, Wednesday, 26'th Apr 2023
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Better Buy: Novo Nordisk vs. Eli Lilly
05:17am, Tuesday, 25'th Apr 2023
Sales of Novo Nordisk's diabetes drug and weight-management drugs are soaring. Eli Lilly's popular new diabetes drug, Mounjaro, could soon earn approval to address chronic weight management.
3 Top-Ranked Stocks Displaying Immense Relative Strength
06:59pm, Monday, 24'th Apr 2023
Stop me if you've heard this before, but stocks making new highs tend to make even higher highs, especially when analysts' positive earnings estimate revisions roll in.
Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race
01:13pm, Monday, 24'th Apr 2023
Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment. The post Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The
Are Medical Stocks Lagging Novo Nordisk (NVO) This Year?
11:28am, Thursday, 20'th Apr 2023
Here is how Novo Nordisk (NVO) and Novartis (NVS) have performed compared to their sector so far this year.
